| 货号 | 3085/50 |
| 别名 | 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1 |
| 供应商 | Tocris |
| 生物活性 | Atypical antipsychotic that displays combined serotonin and dopamine receptor antagonism. Displays high affinity at 5-HT2A receptors with a 5-HT2A/D2 affinity ratio greater than any other clinically available atypical antipsychotics (pKi values are 9.38, 8.88, 8.69, 8.47, 8.32, 8.14, 7.98, 7.49, 7.33 and 6.28 for 5-HT2A, 5-HT2C, 5-HT1D, 5-HT1A, D2, D3,α1, D4, H1 and D1 receptors respectively). |
| 运输条件 | Blue Ice |
| 存放说明 | Ambient |
| 纯度 | >99 % |
| 计算分子量 | 449.4 |
| 分子式 | C21H21ClN4OS.HCl |
| 可溶性/溶解性 | Soluble to 10 mM in DMSO |
| CAS号 | 138982-67-9 |
| 参考文献 | Fellet al (2005) Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav.Brain Res. 160 338. PMID: 15863230. Schmidtet al (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur.J.Pharmacol. 425 197. PMID: 11513838. Seegeret al (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J.Pharmacol.Exp.Ther. 275 101. PMID: 7562537. |